| Document |
Document Title |
|
WO/2014/009274A1 |
The invention relates to AKR1C3 inhibitors and methods for the production thereof, the use thereof for treating and/or preventing diseases, and the use thereof for producing medicaments for treating and/or preventing diseases, in particu...
|
|
WO/2013/160810A2 |
(I)The invention relates to novel novel betulinic acid derivatives and related compounds, and pharmaceutical compositions useful for therapeutic treatment of viral diseases and particularly HIV mediated diseases.
|
|
WO/2013/159225A1 |
The specification relates to a process for preparation of 17-substituted steroid and intermediates useful therein. Embodiments of 17-substituted steroid have been shown as useful for treatment of androgen-dependent disorders, especially ...
|
|
WO/2013/123878A1 |
Provided are acetatic Abiraterone trifluoroacetate, a preparation method and an application of same. The acetatic Abiraterone trifluoroacetate is obtained through a salt-forming reaction between acetatic Abiraterone and trifluoroacetic a...
|
|
WO/2013/121607A1 |
The present invention addresses the problem of providing a copper catalyst which has higher catalytic activity than conventional copper catalysts, is able to be easily recovered, and can be reused repeatedly. The present invention relate...
|
|
WO/2013/057148A1 |
The present invention relates to acid addition salts of 5α-hydroxy-6β-[2-(1H- imidazol-4-yl)ethylamino]cholestan-3β-ol, to their preparation and to applications thereof.
|
|
WO/2013/056181A1 |
Provided herein are 3,3-disubstituted 19-nor- steroidal compounds according to Formula (I) and (III): where R1,R2, R3, R3', R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful fo...
|
|
WO/2013/053691A1 |
The present invention relates to a process for the preparation of 17-substituted steroids and, more particularly, to an improved method of synthesizing abiraterone or derivatives thereof in high yield and purity by means of a key 3-forma...
|
|
WO/2013/045407A1 |
The invention relates to AKR1C3 inhibitors and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of...
|
|
WO/2013/030410A2 |
The present invention relates to processesfor obtaining abirateroneand derivatives thereof, such as abiraterone acetate, by means of a Suzuki coupling through a steroid borate of general formula (IV) or a C-C coupling through a steroid h...
|
|
WO/2013/016725A1 |
Described herein are compounds which either act as pure antiprogestins or as antiprogestins with partial agonistic activity and methods of treating cancer using such compounds.
|
|
WO/2013/000286A1 |
The bufogenin derivatives or their pharmaceutically acceptable salts having the following general formula I, their preparation methods, the pharmaceutical compositions containing such derivatives and their uses are provided. The bufogeni...
|
|
WO/2012/157130A1 |
The invention provides a method for differentiating an adenoma using the 18-oxoF present in the peripheral blood of a primary aldosteronism patient. Moreover, the invention provides a method and compound for determination of the 18-oxoF ...
|
|
WO/2012/145888A1 |
Provided is a method for purifying rocuronium bromide, which comprises: formulating crude rocuronium bromide to be purified into an aqueous solution, distilling off excess residue solvents at reduced pressure, absorbing by adding active ...
|
|
WO/2012/119458A1 |
Disclosed are the general structural formula of LQC-Y as well as the synthesis and use thereof. Pharmacological experiments demonstrated the marked antitumor effect of such compounds. Single day administration of LQC-Y3 to mice at a maxi...
|
|
WO/2012/100411A1 |
A method for preparing rocuronium is disclosed. 2β-(4-Morpholinyl)-16β-(1-pyrrolidinyl)-5α-androstan-3α-
ol-17β-acetate is used as a starting material and is directly reacted with 3-bromopropene at ambient temperature to produce roc...
|
|
WO/2012/083112A2 |
Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula (Z), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII). Also described herein are pharmaceutical compositions that include at least one compound...
|
|
WO/2012/011106A1 |
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...
|
|
WO/2011/089541A1 |
The present invention concerns a method for intracellular delivery of isolated naked nucleic acids into isolated biological tissue or organ, said method comprising at least the steps of: a/ contacting said tissue or organ with an efficie...
|
|
WO/2011/043913A2 |
The instant invention provides for novel cationic lipids with short lipid chains that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides, to facilit...
|
|
WO/2011/029639A2 |
The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.
|
|
WO/2010/136940A1 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2010/126953A1 |
New chemical entities which comprise corticosteroids and phosphorylated β- agonists for use in therapy and compositions comprising and processes for preparing the same are provided.
|
|
WO/2010/123545A2 |
Compounds of Structural Formula I or pharmaceutically acceptable salts thereof, are effective inhibitors of angiogenesis:
|
|
WO/2010/118699A1 |
High purified (2β,3α,5α,16β,17β) -2-(4-morpholinyl)-16-(1-pyrrolidinyl)-androstane-3,17-diol (formula III) or composition containing it and their use in preparing rocuronium bromide (formula I) are disclosed.
|
|
WO/2010/118025A1 |
Described herein are compounds which exhibit progesterone antagonistic effects and methods of treating cancer using such compounds.
|
|
WO/2010/102673A1 |
The present invention relates to new cardiotonic Steroid Compounds of Formula (I) or (II) wherein X1, X2, X3, L, R1, R2, R3, R4, and R5 have the same meaning as that defined in the Claims. The invention also relates to the use of said Co...
|
|
WO/2010/091306A1 |
Prodrugs of C-17-heterocyclic- steroidal drugs providing improved oral bioavailability and phamacokinetics are described. The drugs are inhibitors of human CYP 17 enzyme, as well as potent antagonists of both wild type and mutant androge...
|
|
WO/2010/091303A1 |
Steroidal C-17 nitrogen-containing heterocycles of Formula I:,wherein: the ABCD ring structure is the nucleus of a steroid, or an analog thereof,; X is a group capable of coordinating a heme group of CYP 17, and Y is an hydroxyl function...
|
|
WO/2010/062562A1 |
The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders.
|
|
WO/2010/060215A1 |
Novel chemical agents of Formula I are described herein. More specifically, 2-(N-substituted piperazinyl) pregnane and 2-(N-substituted piperazinyl) androstane derivatives exhibiting cytotoxicity on a variety of cancer cell lines are dis...
|
|
WO/2010/012904A2 |
The present invention relates to novel chemical compounds, in particular cholest-4-en-3-one oxime derivatives, and to the use thereof as medicaments, especially as cytoprotective medicaments, in particular as neuroprotective, cardioprote...
|
|
WO/2010/000070A1 |
The present invention relates to a process for extracting, purifying and isolating cyclopamine from cyclopamine-containing biomass comprising the steps of contacting cyclopamine-containing organic matter with an extractant (e.g., aqueous...
|
|
WO/2009/135449A1 |
The invention relates to novel ligands of the estrogen receptors α and β of general formula (II), which are useful as active substance of pharmaceuticals, for example pharmaceutical compositions useful for hormone replacement therapy, ...
|
|
WO/2009/120565A2 |
Prodrugs of steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at A ring portion of the ABC ring structure of...
|
|
WO/2009/117120A1 |
The present invention provides a purification method for air sensitive steroids, by reacting an amino acid or an analogue thereof with the 21-aldehyde oxidation product of such air sensitive steroids to form an adduct that is separated f...
|
|
WO/2009/082818A1 |
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/082819A1 |
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...
|
|
WO/2009/085879A2 |
|
|
WO/2009/085880A2 |
The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the gener...
|
|
WO/2009/054531A1 |
Disclosed is a liquid crystal aligning agent containing a radiation-sensitive polyorganosiloxane which is obtained by reacting a compound represented by the formula (1) below with a polyorganosiloxane having an epoxy group. (In the formu...
|
|
WO/2009/047101A1 |
New aminooxime derivatives at position 3 of 2-and/or 4-substituted androstanes and androstenes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as he...
|
|
WO/2009/047006A2 |
An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mix...
|
|
WO/2009/016648A2 |
A novel regioselective process for preparing (2ß, 3a, 5a, 16ß, 17ß)-17 acetoxy-3- hydroxy-2- (4-morpholinyl)- 16- (1-pyrrolidinyl) androstane, a known intermediate in the preparation of skeletal muscle relaxant rocuronium bromide in h...
|
|
WO/2008/155141A2 |
A facultative cationic sterol derivate, said sterol derivate has a pka value of between 3.5 and 8 and the general formula Cation-Spacer 2-Y-Spacer 1-X-Sterol wherein X and Y are linking groups and wherein at least on of X and Y is -NH(C=...
|
|
WO/2008/124922A1 |
Compounds having the structure, their salts or N-oxide derivatives: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, a...
|
|
WO/2008/109033A1 |
Described herein are steroid derivatives of fullerene moieties, for example fullerene derivatives in which cholesterol, or a cholesterol moiety, is attached via ester, amide, or ether bonds to one of a variety of "linkers," e.g., chemica...
|
|
WO/2008/093086A1 |
The invention features compounds of formula (I): and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.
|
|
WO/2008/065100A1 |
This invention relates to novel substituted estratrien derivatives of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder requiring the inhibition of a 17β...
|
|
WO/2008/034796A2 |
This invention relates to novel estratrien-triazoles of general formula (I) useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease ...
|
